<?xml version='1.0' encoding='utf-8'?>
<document id="22747259"><sentence text="Paliperidone: a review of clinical trial data and clinical implications."><entity charOffset="0-12" id="DDI-PubMed.22747259.s1.e0" text="Paliperidone" /></sentence><sentence text="Paliperidone, 9-hydroxy-risperidone, is the major metabolite of the atypical antipsychotic risperidone and is available in an oral extended-release (ER) formulation"><entity charOffset="0-12" id="DDI-PubMed.22747259.s2.e0" text="Paliperidone" /><entity charOffset="14-35" id="DDI-PubMed.22747259.s2.e1" text="9-hydroxy-risperidone" /><entity charOffset="91-102" id="DDI-PubMed.22747259.s2.e2" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.22747259.s2.e0" e2="DDI-PubMed.22747259.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22747259.s2.e0" e2="DDI-PubMed.22747259.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22747259.s2.e0" e2="DDI-PubMed.22747259.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22747259.s2.e1" e2="DDI-PubMed.22747259.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22747259.s2.e1" e2="DDI-PubMed.22747259.s2.e2" /></sentence><sentence text=" Paliperidone ER was approved for treating schizophrenia in 2006, and in 2009 it became the first atypical antipsychotic licensed for treating schizoaffective disorder"><entity charOffset="1-13" id="DDI-PubMed.22747259.s3.e0" text="Paliperidone" /></sentence><sentence text=" The short-term efficacy, safety and tolerability of paliperidone ER for patients with schizophrenia were demonstrated in three pivotal 6-week, randomized, double-blind, placebo-controlled studies"><entity charOffset="53-65" id="DDI-PubMed.22747259.s4.e0" text="paliperidone" /></sentence><sentence text=" Data from the long-term trial showed that paliperidone ER is also effective in preventing relapse of schizophrenia"><entity charOffset="43-55" id="DDI-PubMed.22747259.s5.e0" text="paliperidone" /></sentence><sentence text=" Two randomized, placebo-controlled, short-term studies have documented the efficacy and tolerability of paliperidone ER in the treatment of schizoaffective disorder, but no long-term or maintenance study has been conducted in patients with schizoaffective disorder"><entity charOffset="105-117" id="DDI-PubMed.22747259.s6.e0" text="paliperidone" /></sentence><sentence text=" Two 3-week, randomized, double-blind, placebo-controlled studies showed that paliperidone ER is significantly superior to placebo for treating patients with bipolar disorder, but the results were driven by certain subpopulations"><entity charOffset="78-90" id="DDI-PubMed.22747259.s7.e0" text="paliperidone" /></sentence><sentence text=" Limited evidence suggests that paliperidone ER can potentially be superior to quetiapine and risperidone"><entity charOffset="32-44" id="DDI-PubMed.22747259.s8.e0" text="paliperidone" /><entity charOffset="79-89" id="DDI-PubMed.22747259.s8.e1" text="quetiapine" /><entity charOffset="94-105" id="DDI-PubMed.22747259.s8.e2" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.22747259.s8.e0" e2="DDI-PubMed.22747259.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22747259.s8.e0" e2="DDI-PubMed.22747259.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22747259.s8.e0" e2="DDI-PubMed.22747259.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22747259.s8.e1" e2="DDI-PubMed.22747259.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22747259.s8.e1" e2="DDI-PubMed.22747259.s8.e2" /></sentence><sentence text=" However, few direct head-to-head comparisons between paliperidone ER and other antipsychotics have been conducted to confirm these results"><entity charOffset="54-66" id="DDI-PubMed.22747259.s9.e0" text="paliperidone" /></sentence><sentence text=" The distinctive pharmacological characteristics of paliperidone ER, including smooth fluctuations in plasma drug concentrations, predominantly renal excretion, low risk of causing hepatic impairment and low drug-drug interaction, might provide important clinical advantages compared with risperidone"><entity charOffset="52-64" id="DDI-PubMed.22747259.s10.e0" text="paliperidone" /><entity charOffset="289-300" id="DDI-PubMed.22747259.s10.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.22747259.s10.e0" e2="DDI-PubMed.22747259.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22747259.s10.e0" e2="DDI-PubMed.22747259.s10.e1" /></sentence><sentence text=" However, certain side effects require clinical attention" /><sentence text=" The rate of extrapyramidal side effects was considerably higher than that of a placebo at doses â‰¥9 mg/day" /><sentence text=" The risks for orthostatic hypotension, prolongation of the corrected QT interval and hyperprolactinaemia are also concerns" /><sentence text=" This review summarizes the currently published data on paliperidone ER for treating patients with schizophrenia, schizoaffective disorder and bipolar disorder, and suggests its appropriate use in clinical practice"><entity charOffset="56-68" id="DDI-PubMed.22747259.s14.e0" text="paliperidone" /></sentence><sentence text="" /></document>